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Carotid endarterectomy was performed with lower
stroke and death rates than carotid artery stenting
in the United States in 2003 and 2004
James T. McPhee, MD,a Joshua S. Hill, MD, MS,b Rocco G. Ciocca, MD,b Louis M. Messina, MD,b
and Mohammad H. Eslami, MD,b Worcester, Mass
Objective: Although carotid endarterectomy (CEA) is the gold standard for the treatment of carotid artery stenosis, the
recent United States Food and Drug Administration approval of carotid artery stenting (CAS) may have led to its
widespread use outside of clinical trials and registries. This study compared in-hospital postoperative stroke andmortality
rates after CAS and CEA at the national level.
Methods: The Nationwide Inpatient Sample (NIS) was queried to identify all patient-discharges that occurred for
revascularization of carotid artery stenosis. The International Classification of Diseases, 9th Revision, Clinical Modification
procedure codes for CEA (38.12), CAS (00.63), and insertion of noncoronary stents (39.50, 39.90) were used in
conjunction with the diagnostic codes for carotid artery stenosis, with (433.11) and without (433.10) stroke. Primary
outcome measures included in-hospital postoperative stroke and death rates. Multivariate logistic regressions were
performed to evaluate independent predictors of postoperative stroke and mortality. Adjustment was made for age, sex,
medical comorbidities, admission diagnosis, procedure type, year, and hospital type.
Results: During the calendar years 2003 and 2004, an estimated 259,080 carotid revascularization procedures were
performed in the United States. CAS had a higher rate of in-hospital postoperative stroke (2.1% vs 0.88%, P< .0001) and
higher postoperative mortality (1.3% vs 0.39%) than CEA. For asymptomatic patients (92%), the postoperative stroke rate
was significantly higher for CAS than CEA (1.8% vs 0.86%, P < .0001), but the mortality rate was similar (0.44% vs
0.36%, P  .36). For symptomatic patients (8%), the rates for postoperative stroke (4.2% vs 1.1%, P < .0001) and
mortality (7.5% vs 1.0%, P < .0001) were significantly higher after CAS. By multivariate regression, CAS was
independently predictive of postoperative stroke (odds ratio [OR], 2.49; 95% confidence interval [CI], 1.91 to 3.25).
CAS was also associated with in-hospital postoperative mortality for asymptomatic (OR, 2.37; 95% CI, 1.46 to 3.84) and
symptomatic (OR, 2.64; 95% CI, 1.89 to 3.69) patients.
Conclusions: As determined from a large representative national sample including the years 2003 and 2004, the
in-hospital stroke rate after CAS for asymptomatic patients was twofold higher than after CEA. For symptomatic
patients, the respective in-hospital stroke and mortality rates were fourfold and sevenfold higher. These unexpected
results indicate that further randomized controlled trials with homogenous symptomatic and asymptomatic patient
groups should be performed. (J Vasc Surg 2007;46:1112-8.)Carotid artery stenting (CAS) was introduced in the
early 1990s as a potentially safer, less invasive alternative to
carotid endarterectomy (CEA) for the treatment of symp-
tomatic and asymptomatic patients with carotid artery ste-
nosis. Despite its approval by the United States Food and
Drug Administration in 2004 for use in symptomatic pa-
tients judged to be high risk for CEA,1 the role of CAS in
the management of patients with carotid artery stenosis
remains disputed. Although CEA has been shown conclu-
sively to reduce the risk of stroke more than optimal med-
ical therapy alone for patients with symptomatic2,3 and
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1112asymptomatic4,5 carotid artery stenosis, similar results from
prospective studies of CAS are lacking.
The minimally invasive nature of CAS makes it an
appealing treatment option for severe carotid artery steno-
sis. This fact may lead to increased usage over time6 beyond
its currently approved indications specifically because of
varying interpretations of what constitutes “high” surgical
risk.
Because high-surgical-risk patients were excluded
from the landmark studies that showed CEA is superior
to optimal medical therapy alone for symptomatic2 and
asymptomatic5 carotid artery stenosis, controversy has
emerged about the appropriate intervention for this
high-risk patient population. This is partly due to the
results of certain industry-based trials,7,8 the designs and
outcomes of which have been critiqued by others,9-12
which have concluded that CAS is not an inferior modal-
ity to CEA in terms of composite stroke, death, or
myocardial infarction (MI) rates7,8 despite recent pub-
licly funded randomized trials that have concluded the
contrary.13,14
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proved reimbursement for carotid stenting in high-risk
symptomatic patients. Because of the conflicting results
from nonrandomized trials and the absence of a compara-
tive analysis at the national level of the morbidity and
mortality for CAS and CEA, it is difficult for physicians to
make definitive recommendations for their patients. For
this reason, we undertook a retrospective observational
population-based study to determine current in-hospital
postprocedural stroke and mortality rates after CAS and
CEA in symptomatic and asymptomatic patients in the
United States.
METHODS
To evaluate outcomes for CAS and CEA at the national
level, data were obtained from the Nationwide Inpatient
Sample (NIS) for the calendar years 2003 and 2004, the
most recent years available. The NIS is the most compre-
hensive database of its kind and includes 100% of abstracted
discharge data from a national survey of 20% of all nonfed-
eral acute-care hospitals in the United States.15 These data
are linked to the American Hospital Association’s (AHA)
annual survey of hospitals by corresponding year to allow
analyses of hospital level factors such as bed size, teaching
status, and geographic location. The NIS provides a
weighting strategy to allow estimates to be made at the
national level. EachNIS sample hospital’s weight is equal to
the number of hospitals it represents during the year.
Because 20% of the AHA’s hospitals are sampled each year,
the given hospital’s weight is approximately five.15 To
calculate national estimates, these sample weights are incor-
porated into the analyses, a technique described by other
authors.16-18 All statistical analyses are based on these
survey weights; therefore, all data provided in the results
section represent weighted frequencies.
All CAS and CEA procedures performed during the
2-year period were identified by linking the International
Classification of Diseases Ninth Revision, Clinical Modifica-
tion (ICD-9CM)19 procedural codes for CEA and CAS to
the appropriate primary diagnostic codes for carotid artery
stenosis with and without mention of stroke. Before 2004,
because the ICD-9CM procedure code specific to CAS
(00.63) did not exist, patients were coded under other less
specific procedural codes (Appendix, online only). Carotid
stent patients were identified by first querying the database
for the procedural codes for “angioplasty or atherectomy of
non-coronary vessel (39.50)” and “insertion of non-coronary
artery stent (39.90).” These less specific procedure codes
were then linked to only those patients with a principal
discharge diagnosis of carotid artery stenosis.
To more accurately analyze the primary outcome mea-
sures of postoperative stroke and mortality for the two
techniques, patients were classified as symptomatic or
asymptomatic. If a patient’s principal discharge diagnosis
was “carotid artery stenosis without mention of stroke”
with no accompanying secondary diagnoses for transient
ischemic attack (TIA), they were classified as asymptomatic.
If a patient’s principal discharge diagnosis was “carotidartery stenosis with stroke” or if there was no mention of
stroke but a secondary diagnosis code included that for
TIA, patients were classified as symptomatic.
The primary outcome measures for this retrospective
study were in-hospital postoperative stroke and death. Post-
operative strokewas defined as carrying an ICD-9CMsecond-
ary diagnostic code of “post-operative stroke (997.02).” Post-
operative death was defined as any death during the same
hospital stay regardless of postoperative interval.
All statistical analyses were performed using the ad-
vanced survey procedures in the SAS 9.1 software (SAS
Institute, Cary, NC). Categoric variables were analyzed by
Rao-Scott 2, and continuous variables were analyzed by
survey-weighted analysis of variance (ANOVA), with a
value of P  .05 considered statistically significant.
Separate multivariate logistic regressions were per-
formed to determine which factors independently affected
postoperative stroke and mortality. The logistic regressions
were performed with adjustments made for the covariates
of patient age, gender, hospital teaching type, year of
procedure, presentation type (symptomatic vs asymptom-
atic), procedure type (CEA vs CAS), and payer status, as
well as the specific comorbid medical conditions of coro-
nary artery disease/previous MI, congestive heart failure,
valvular heart disease, diabetes mellitus, chronic lung dis-
ease, hypertension, renal failure, and obesity, with the use
of comorbidity software previously designed for use with
national databases.20 An interaction term between the
treatment method (CAS vs CEA) and symptom status was
evaluated and found to be significant for postoperative
death; therefore, separate odds ratios (OR) and 95% confi-
dence intervals (CI) of postoperative death are provided
according to the presence or absence of symptoms.
RESULTS
Patient characteristics. In the United States during
the calendar years 2003 and 2004, an estimated 259,080
patient discharges occurred after CEA or CAS. Of these,
245,045 patients underwent CEA (94.6%) and 14,035
underwent CAS (5.4%). The mean age was 71.1 years
[standard error of the mean, 0.08], and 57% were men.
Almost all patients (92%) underwent treatment for asymp-
tomatic carotid artery stenoses. Of those that underwent
treatment for symptomatic stenoses, 62% were for symp-
toms of transient ischemic attack (TIA), and 38% were for
symptoms of stroke (Table I). The percentage of asymp-
tomatic and symptomatic patients treated at teaching vs
nonteaching hospitals was similar. Of those treated at
teaching hospitals, 8.1% were symptomatic compared with
7.9% at nonteaching hospitals (P  .69).
Clinical presentation. On average, patients present-
ing with symptoms of TIA and stroke were older than the
asymptomatic patients (74.8 vs 71.6 years, P .0001). The
distribution of comorbid conditions was not uniform by
clinical presentation (Fig 1).
Univariate analysis of asymptomatic patient
characteristics. The characteristics of the patients under-
going CEA and CAS were comparable in terms of median
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specifically, diabetes (P  .62), coronary artery disease/
previousMI (P .94), valvular heart disease (P .44), and
obesity (P  .15). Patients undergoing CEA had a higher
mean age (71.2 vs 70.5 years, P  .0001) and a greater
Table I. Carotid revascularization patient characteristics,
2003 and 2004*
Factor Overall, No. (%) Mortality, % P
Patients, No. 259,080 (100) 0.44 NA
Age, y .0002
Mean (SEM) 71.1 (0.08)
Median (range) 72 (21-97)
60 32,287 (13) 0.29
60-69 73,001 (28) 0.31
70 153,792 (59) 0.53
Sex .52
Men 148,455 (57) 0.46
Women 110,395 (43) 0.42
Presentation type .0001
Asymptomatic 238,390 (92) 0.34
Symptomatic 20,690 (8) 1.6
TIA 12,900 (5) 0.43 .96
Stroke 8,003 (3) 3.4 .0001
Procedure type .0001
CEA 245,045 (95) 0.39
CAS 14,035 (5) 1.3
Hospital type .49
Nonteaching 142,352 (55) 0.42
Teaching 116,728 (45) 0.47
Payer .23
Private/Medicare 246,466 (95) 0.49
Medicaid/self-pay 12,370 (5) 0.29
CEA, Carotid endarterectomy; CAS, carotid artery stenting;NA, not appli-
cable; SEM, standard error of the mean; TIA, transient ischemic attack.
*Univariate analysis of overall in-patient mortality is included.
Fig 1. This bar graph compares the patient characteristics of
those presenting as asymptomatic (black) or symptomatic (grey)
carotid artery stenosis, 2003 and 2004. CEA, Carotid endarterec-
tomy;HTN, hypertension;DM, diabetes mellitus;COPD, chronic
obstructive pulmonary disease; CAD, coronary artery disease;
CHF, congestive heart failure; *P  .05.prevalence of hypertension (P  .011) and chronic lungdisease (P .0004). In contrast, patients undergoing CAS
had a higher prevalence of congestive heart failure (P 
.0001) and renal failure (P  .038) than the CEA group
and were more likely to be treated at a teaching hospital (P
 .0001; Table II).
Univariate analysis of postoperative morbidity and
mortality. For asymptomatic patients with carotid artery
stenosis, the postoperative stroke rate was twofold higher
after CAS compared with CEA (1.8 vs 0.86%, P  .0001),
but the crude in-hospital mortality rate after CEA and CAS
was similar (.34% vs 0.44%, P  .36). The two procedures
were similar in terms of postoperative MI (2.0% vs 1.7%, P
 .31; Table III).
Univariate analysis of symptomatic patient
characteristics. Patients undergoing CEA had a higher
mean age (70.1 vs 68.6 years, P  .0001) and a greater
prevalence of the comorbid conditions of hypertension
(67.3% vs 60.3%, P  .023) and chronic lung disease
(21.2% vs 14.1%, P  .001). In contrast, the CAS patients
had a higher prevalence of renal failure (8.6% vs 2.4%, P 
.0001). The two groups had similar rates of diabetes (P 
.19), coronary artery disease (P  .37), congestive heart
failure (P  .37), valvular heart disease (P  .93), and
obesity (P  .35; Table II).
Univariate analysis of postoperative morbidity and
mortality. For symptomatic patients with carotid artery
stenosis, the postoperative stroke rate after CAS was nearly
fourfold higher than that for CEA (4.2% vs 1.1%, P 
.0001). Similarly, the CAS patients had a sevenfold higher
postoperative mortality rate than the CEA patients (7.5% vs
1.0%, P .0001). The postoperativeMI rate was similar for
CAS (2.2%) and CEA (2.0%; P  .73; Table III).
Outcomes for octogenarians. By separate analysis,
the percentage of octogenarians in the two procedure
groups was similar. Of the open repair group, 19.7% of
patients were aged 80 year compared with 18.9% in the
endovascular group (P  .42). The postoperative stroke
rate for octogenarians was increased in the endovascular
group compared with the open repair group (3.0% vs 1.0%,
P  .0001), but the mortality rates were similar (1.2% vs
0.8%, P  .19).
Multivariate analysis of postoperative stroke.
Carotid artery stenting had higher odds of being compli-
cated by postoperative stroke than did CEA (OR, 2.49;
95% CI 1.91 to 3.25). Other variables that independently
predicted stroke included older patient age group: 70 vs
60 years (OR, 1.56; 95% CI, 1.10 to 2.25), chronic lung
disease (OR, 1.31; 95 % CI, 1.07 to 1.61), congestive heart
failure (OR, 2.25; 95% CI, 1.70 to 2.98), the presence of
symptoms (OR, 1.47; 95% CI, 1.11 to 1.95), and postop-
erative MI (OR, 2.42; 95% CI, 1.52 to 3.84; Table IV,
Fig 2).
Multivariate analysis of postoperative mortality.
By multivariate logistic regression, which included adjust-
ments for multiple covariates, the performance of CAS was
independently predictive of increased postoperative mor-
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3.84) and symptomatic patients (OR, 2.64; 95% CI, 1.89
to 3.69; Table IV, Fig 3). Other independent predictors of
in-hospital mortality included presenting with symptoms of
TIA or stroke (OR, 4.01; 95% CI, 2.93 to 5.51), older
patient age (OR, 1.50; 95% CI, 1.09-2.06), a history of
congestive heart failure (OR, 3.74; 95% CI, 2.58 to 5.42),
obesity (OR, 2.23; 95% CI, 1.17 to 4.26), and renal failure
(OR, 2.50; 95% CI, 1.45 to 4.31). Similarly, certain post-
operative complications were strongly associated with in-
hospital mortality, including MI (OR, 4.61; 95% CI, 2.62
Table II. Patient characteristics for revascularization of as
Factor Overall
Asy
CEA
Characteristic
Overall No. 259,080 226,111
Patient age, y
Mean (SEM) 71.1 (0.08) 71.2 (0.08) 7
Median (range) 72 (21-97) 72 (21-97)
Age groups, %
60 12.5 11.9
60-69 28.2 28.2
70 59.4 59.9
Sex, %
Men 57.4 56.9
Women 42.6 43.1
Comorbid conditions, %
Hypertension 70.2 70.8
Diabetes mellitus 25.1 25.4
Chronic lung disease 18.9 19.0
CAD/MI 11.6 11.8
CHF 6.4 6.2
Valvular disease 6.1 6.0
Renal failure 2.1 2.1
Obesity 3.7 3.7
Hospital type, %
Teaching 45 43.1
Nonteaching 55 56.9
Insurance type, %
Private/Medicare 95.2 95.7
Medicaid/self-pay 4.8 4.3
CAD, Coronary artery disease; CAS, carotid artery stenting; CEA, carotid en
applicable; SEM, standard error of the mean.
Table III. Surgical outcomes after carotid
endarterectomy and carotid artery stenting for
asymptomatic and symptomatic patients
Factor Overall
Asymptomatic Symptomatic
CEA CAS P CEA CAS P
Postoperative,
%
Mortality 0.44 0.34 0.44 .36 1.0 7.5 .0001
Stroke 0.95 0.86 1.8 .0001 1.1 4.2 .0001
MI 1.7 1.7 2.0 .31 2.0 2.2 .73
CAD, Coronary artery disease; CAS, carotid artery stenting; CEA, carotid
endarterectomy; MI, myocardial infarction.to 8.12) and stroke (OR, 31.0; 95% CI, 21.5 to 44.7).DISCUSSION
This large population-based study has demonstrated
that during the calendar years 2003 and 2004, CEA con-
tinued to be associated with lower overall rates of postop-
erative stroke (0.88% vs 2.1%, P  .0001) and mortality
(0.39% vs 1.3%, P  .0001) than CAS. For asymptomatic
patients, the mortality rate for CEA and CAS was similar
(0.36% vs 0.44%, P  .36); however, the postoperative
stroke rate of 1.8% for CAS was more than twofold higher
than the 0.86% rate for CEA (P  .0001). Patients with
symptomatic stenoses who underwent CAS had a sevenfold
higher postoperative mortality rate (7.5% vs 1.0%, P 
.0001) and nearly fourfold higher postoperative stroke rate
(4.2% vs 1.1%, P  .0001) than those undergoing CEA.
These observations were confirmed by multivariate logistic
regression, which demonstrated that CAS was indepen-
dently predictive of postoperative mortality and stroke
(OR, about 2.4 for both), despite adjustment for comorbid
conditions, postoperative complications, and presentation
of “symptomatic” vs “asymptomatic” carotid artery ste-
nosis.
Studies with conflicting results have been published
comparing outcomes for CAS and CEA. The observations
from this administrative study compare favorably with
other population-based series limited to in-hospital values,
omatic and symptomatic carotid artery stenosis
atic Symptomatic
AS P CEA CAS P
278 NA 18,933 1757 NA
0.35) .0001 70.1 (0.19) 68.6 (0.71) .0001
24-96) 71 (31-97) 70 (27-92)
.039 .20
9 17.5 20.7
2 26.8 28.2
9 55.7 51.1
.045 .05
3 61.1 55.8
7 38.9 44.2
7 .011 67.3 60.3 .023
8 .62 21.4 24.5 .19
0 .0004 21.3 14.1 .001
7 .94 9.8 8.4 .37
1 .0001 7.5 9.8 .13
4 .44 6.9 6.8 .93
7 .038 2.4 8.6 .0001
0 .15 4.4 3.5 .35
.0001 .0001
1 41.6 76.0
9 58.4 24.0
.002 .017
6 92.5 87.7
4 7.5 12.3
rectomy; CHF, congestive heart failure;MI,myocardial infarction;NA, notympt
mptom
C
12,
0.5 (
72 (
13.
29.
56.
59.
40.
66.
25.
15.
11.
9.
6.
2.
3.
81.
18.
92.
7.
dartewith similar CEA mortality and stroke rates21 as well as an
JOURNAL OF VASCULAR SURGERY
December 20071116 McPhee et alobserved increase in perioperative stroke (2.13% vs 1.28%)
and mortality (3% vs 0.5%) rates for CAS compared with
CEA at the national level.6 Unlike the current work, these
prior studies did not separately analyze outcomes for symp-
tomatic and asymptomatic patient populations. They were
also limited to study years during which CAS was being
evaluated in clinical trials and therefore may have repre-
sented higher than expected stroke and mortality results
than contemporary CAS data.
The observations of the current work also agree with
those observed by the authors of the Endarterectomy ver-
sus Stenting in Patients with Symptomatic Severe Carotid
Stenosis (EVA-3S) study of 527 subjects, which found a
30-day risk of any stroke or death of 9.6% for CAS vs 3.9%
for CEA (relative risk, 2.5).14 Of note, the EVA-3S study
Table IV. Multivariate analyses of in-hospital mortality
and postprocedural stroke for carotid revascularization,
2003 and 2004
Factor
In-hospital
mortality
Postprocedural
stroke
OR 95% CI OR 95% CI
Sex
Men (vs women) 1.08 .82-1.43 1.0 .83-1.20
Age group
70 (vs 60) 1.56 .93-2.62 1.56 1.10-2.25
70 (vs 60-69) 1.50 1.09-2.06 1.11 .90-1.35
Insurance type
Private (vs
Medicaid/self-
pay)
1.59 .63-4.0 .97 .62-1.53
Co-morbid conditions
(vs none)
Hypertension .66 .50-.89 .85 .70-1.04
Diabetes .70 .49-1.02 1.15 .94-1.41
Chronic lung disease 1.30 .93-1.84 1.31 1.07-1.61
CAD/MI .40 .22-.73 .64 .47-.86
Congestive heart
failure
3.74 2.58-5.42 2.25 1.70-2.98
Valvular heart
disease
.97 .59-1.58 .74 .50-1.10
Obesity 2.23 1.17-4.26 .97 .59-1.61
Renal failure 2.50 1.45-4.31 .83 .46-1.48
Presentation type
Symptomatic (vs
asymptomatic)
4.01 2.93-5.51 1.47 1.11-1.95
CAS vs CEA
Asymptomatic 2.37 1.46-3.84 2.49 1.91-3.25
Symptomatic 2.64 1.89-3.69
Hospital teaching
status
Nonteaching (vs
teaching)
.99 .68-1.28 1.17 .95-1.44
Post-op complications
(vs none)
MI 4.61 2.62-8.12 2.42 1.52-3.84
Stroke 31.0 21.5-44.7 NA NA
Acute renal failure 2.69 0.96-7.56 1.22 .44-3.34
CAD, Coronary artery disease; CAS, carotid artery stenting; CEA, carotid
endarterectomy; CI, confidence intervals; MI, myocardial infarction; NA,
not applicable; OR, odds ratio.was stopped early owing to concerns of safety and futility inthe CAS arm. The authors of a recent case–control series of
301 subjects similarly concluded that CAS was predictive of
30-day stroke compared with CEA (hazard ratio, 3.9; 95%
CI, 1.6 to 9.4, P  .0002).22
In contrast, several industry-sponsored registries, in-
cluding the ACCULINK for Revascularization of Carotids
inHigh-Risk patients (ARCHeR) trial and the Stenting and
Angioplasty with Protection in Patients at High Risk for
Endarterectomy (SAPPHIRE), have concluded that CAS is
a noninferior method to CEA in patients at high risk for
surgery.7,8 These latter two studies have been criticized by
others because of their methodology, including the heter-
ogeneous population of symptomatic and asymptomatic
case-mix,12 the power of the study,10 and the validity of a
noninferiority study performed on nonrandomized data
Fig 2. This chart demonstrates the odds ratios with 95% confi-
dence intervals for postoperative stroke after carotid artery revas-
cularization by carotid artery stenting (CAS) or carotid endarter-
ectomy (CEA). CAS was predictive of postoperative stroke by
logistic regression. COPD, Chronic obstructive pulmonary dis-
ease; CHF, congestive heart failure.
Fig 3. The odds ratios with 95% confidence intervals are pre-
sented for postoperative death after carotid artery revascularization
by carotid artery stenting (CAS) or carotid endarterectomy
(CEA). CAS was predictive of postoperative death by logistic
regression. CHF, Congestive heart failure.using a historical control for the surgical arm.12,23
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stroke after CAS of 4.3% in their mostly (76%) asymptom-
atic patient population, which is similar to the 4.2% post-
operative stroke rate observed for symptomatic patients
undergoing CAS in the current work. The CAS-associated
stroke rate in the ARCHeR study is also substantially higher
than the CEA-associated stroke rate of 1.1% in this work
and others, which typically report values of 1.3% to
2.1%.24,25 We note that these previous studies typically
report 30-day stroke and mortality rates, whereas the cur-
rent work is limited to in-hospital rates only, which may
reflect falsely lower rates by comparison. Further, the crite-
ria for what constitutes “high-risk” may vary widely based
on the methodology of these studies; likewise, individual
practitioners may have differing definitions of what consti-
tutes “high risk.”
The current data do not explain why symptomatic
patients undergoing CAS had significantly higher rates of
mortality and stroke than those undergoing CEA. This
study found that the CEA patients were older, and with the
exception of renal failure, had either similar (diabetes mel-
litus, coronary artery disease, congestive heart failure, val-
vular heart disease, obesity) or more severe (hypertension,
chronic obstructive pulmonary disease) comorbidity pro-
files than the CAS patients. Of note, characteristics such as
previous neck surgery, radiation, and carotid vessel mor-
phology, and the use of embolic protection device are not
available in this administrative data set.
The asymptomatic patients in this study who under-
went CEA and CAS were similar in age (median, 72 years)
and evenly matched for prevalence of significant medical
comorbid conditions (Table III). Despite this similarity,
overall the postoperative stroke rate was significantly
greater for the CAS group (1.8% vs 0.86%, P  .0001). Of
importance, by multivariate logistic regression, which in-
cluded the variable for symptom status and comorbid con-
ditions, CAS remained independently predictive of postop-
erative stroke.
The limitations of analyses based on administrative data
sets such as the NIS in terms of miscoded and missing data
are well known.26 The analysis in the current study found
the percentage of patients treated for asymptomatic carotid
artery stenosis (92%) was higher than expected, a fact that
warrants further investigation. A patient with a completed
stroke who was admitted without an active stroke could
conceivably have been misclassified into the asymptomatic
cohort. Likewise, if an in-hospital stroke after a procedure
was not properly coded as iatrogenic (997.02), the current
analysis could have potentially missed or misclassified a
percentage of postoperative strokes. It is, however, logical
that any potential misclassifications would occur without
bias toward any particular procedure group.
In addition, evaluating patient case-mix including the
severity of comorbid medical conditions and postoperative
complications is difficult to ascertain at the population
level.27 Similarly unknown is the severity of complications
such as postoperative stroke and MI. To further compare
CEA and CAS patient groups, this clinical data would bevaluable. In this study, however, the variables of greatest
interest, including diagnosis type, procedure type per-
formed, and in-hospital mortality are reliably coded in the
NIS.
Before October 2004, no dedicated ICD-9CM proce-
dural code for CAS existed, and it was therefore previously
coded under other less-specific codes, which may lead to
some inaccuracy. The deidentification of patients in the
NIS precludes independent coding validation; however, by
linking the codes for endovascular angioplasty and stenting
with the appropriate diagnostic codes for carotid artery
stenosis (primary diagnosis only), the CAS patients should
be appropriately classified. This two-step technique to an-
alyze peripheral stenting procedures was previously de-
scribed by Nowygrod et al.6
In addition, in-hospital outcomes, including mortality
and stroke, are somewhat limited measures of overall suc-
cess. Ideally, more long-term information such as 30-day
and 1-year follow-up would be used to compare the dura-
bility of one procedure vs another; however, they are not
available in this data set.
With surgical innovation, less invasive therapies with
potential benefits may lead to rapid diffusion of the tech-
nology. In the case of CAS, this issue is complicated by the
multidisciplinary backgrounds of the physicians performing
the procedure, some of whom would not otherwise be
providing care for patients with carotid artery occlusive
disease, as might be the case for cardiologists. Although
the technology for CAS will undoubtedly improve, and one
day it may replace CEA as the treatment of choice for some
patient populations, this paradigm shift should be predi-
cated on superior short- and long-term results of prospec-
tive randomized trials and not technical feasibility and
potential benefit.
CONCLUSION
During the period of this study, 2003 and 2004, within
the limitations of data obtained from administrative data
sets, CEA in the United States was performed with lower
risk of postoperative stroke and death than CAS in symp-
tomatic and asymptomatic patients with carotid artery ste-
nosis. These unexpected differences in observed outcomes
are not readily explained by differences in age or the prev-
alence of medical comorbidities. Further randomized con-
trolled studies with homogenous symptomatic and asymp-
tomatic cohorts should be performed to determine what
role CAS will play in the treatment of patients with carotid
artery stenosis.
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procedural codes
Diagnosis Diagnostic code
Carotid artery occlusion and stenosis
without mention of cerebral
infarction
433.10 C
Carotid artery occlusion and
Stenosis with cerebral infarction
433.11 A
Multiple and bilateral carotid artery
occlusion and stenosis without
mention of cerebral infarction
433.30 E
Multiple and bilateral carotid artery
occlusion and stenosis with
cerebral infarction
433.31 In
Transient cerebral ischemia 435.9 P
Amaurosis fugax 362.34f Diseases, 9th Revision, Clinical Modification diagnostic and
Procedure Procedural code
arotid endarterectomy 38.12
ngioplasty or atherectomy of noncoronary vessel 39.50
ndovascular repair of vessel 39.7
sertion of noncoronary artery stent or stents 39.90
ercutaneous insertion of carotid artery stent 00.63
